{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:48:45Z","timestamp":1786996125023,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA204301"],"award-info":[{"award-number":["R01CA204301"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA258997"],"award-info":[{"award-number":["R01CA258997"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.radonc.2023.109720","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T13:19:38Z","timestamp":1685020778000},"page":"109720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?"],"prefix":"10.1016","volume":"185","author":[{"given":"Evan D.H.","family":"Gates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-4404","authenticated-orcid":false,"given":"Daniel S.","family":"Hippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert J.","family":"Vesselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7581-770X","authenticated-orcid":false,"given":"Stephen R.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109720_b0005","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.radonc.2023.109720_b0010","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1078-0432.CCR-17-3269","article-title":"Beyond concurrent chemoradiation: the emerging role of PD-1\/PD-L1 inhibitors in stage III lung cancer","volume":"24","author":"McCall","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.radonc.2023.109720_b0015","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-World safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: a systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiation Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109720_b0020","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2217\/imt-2021-0341","article-title":"Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors","volume":"14","author":"Guberina","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.radonc.2023.109720_b0025","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.radonc.2023.109720_b0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12672-022-00548-4","article-title":"Radiation and immune checkpoint inhibitor-mediated pneumonitis risk stratification in patients with locally advanced non-small cell lung cancer: role of functional lung radiomics?","volume":"13","author":"Thomas","year":"2022","journal-title":"Discov Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0035","first-page":"1930","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109720_b0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2023.109720_b0045","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.cllc.2020.02.025","article-title":"Immune-Related pneumonitis after chemoradiotherapy and subsequent immune checkpoint blockade in unresectable stage III non\u2013small-cell lung cancer","volume":"21","author":"Naidoo","year":"2020","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109720_b0050","first-page":"428","article-title":"Personalizing radiotherapy prescription dose using genomic markers of radiosensitivity and normal tissue toxicity in NSCLC","volume":"16","author":"Scott","year":"2021","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109720_b0055","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","article-title":"Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis","volume":"22","author":"Scott","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0060","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.cllc.2022.08.001","article-title":"18F-FDG PET\/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-small cell lung cancer","volume":"23","author":"Peng","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109720_b0065","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-019-04388-3","article-title":"PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET\/CT response assessment","volume":"46","author":"Iravani","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2023.109720_b0070","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.radonc.2017.08.007","article-title":"Mid-radiotherapy PET\/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer","volume":"125","author":"Gensheimer","year":"2017","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0075","first-page":"1514","article-title":"Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer","volume":"53","author":"van Elmpt","year":"2012","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1016\/j.radonc.2023.109720_b0080","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2018.10.006","article-title":"Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer","volume":"132","author":"Kong","year":"2019","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0085","doi-asserted-by":"crossref","first-page":"1014063","DOI":"10.3389\/fimmu.2022.1014063","article-title":"Prognostic value of 18F-FDG PET\/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Ling","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2023.109720_b0090","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.radonc.2017.06.022","article-title":"Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III study","volume":"124","author":"M\u00f8ller","year":"2017","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","article-title":"The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)","volume":"131","author":"van Diessen","year":"2019","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0100","first-page":"415","article-title":"Implementation of FDG-PET\/CT imaging methodology for quantification of inflammatory response in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668\/RTOG 0235 trial","volume":"11","author":"Jahangiri","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2023.109720_b0105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00259-018-4154-5","article-title":"A prospective study of the feasibility of FDG-PET\/CT imaging to quantify radiation-induced lung inflammation in locally advanced non-small cell lung cancer patients receiving proton or photon radiotherapy","volume":"46","author":"Jahangiri","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2023.109720_b0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.semradonc.2020.11.007","article-title":"Treatment intensification in locally advanced\/unresectable NSCLC through combined modality treatment and precision dose escalation","volume":"31","author":"Zeng","year":"2021","journal-title":"Seminars Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0115","doi-asserted-by":"crossref","unstructured":"O JH, Lodge MA, Wahl RL. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0. Radiology. 2016;280(2):576-584. https:\/\/doi.org\/10.1148\/radiol.2016142043.","DOI":"10.1148\/radiol.2016142043"},{"key":"10.1016\/j.radonc.2023.109720_b0120","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/mp.12308","article-title":"Functional lung avoidance and response-adaptive escalation (FLARE) RT: multimodality plan dosimetry of a precision radiation oncology strategy","volume":"44","author":"Lee","year":"2017","journal-title":"Medical Phys"},{"key":"10.1016\/j.radonc.2023.109720_b0125","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/RLU.0000000000003774","article-title":"Reliability of quantitative 18F-FDG PET\/CT imaging biomarkers for classifying early response to chemoradiotherapy in patients with locally advanced non-small cell lung cancer","volume":"46","author":"Horn","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.radonc.2023.109720_b0130","article-title":"Prognostic value of early fluorodeoxyglucose-positron emission tomography response imaging and peripheral immunologic biomarkers: substudy of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer","volume":"7","author":"Bowen","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0135","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Statistics in Medicine"},{"key":"10.1016\/j.radonc.2023.109720_b0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.0006-341X.2001.00114.x","article-title":"A solution to the problem of monotone likelihood in Cox regression","volume":"57","author":"Heinze","year":"2001","journal-title":"Biometrics"},{"key":"10.1016\/j.radonc.2023.109720_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002822","article-title":"Chapter 11: Genome-wide association studies","volume":"8","author":"Bush","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.radonc.2023.109720_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03610927408827101","article-title":"A dendrite method for cluster analysis","volume":"3","author":"Calinski","year":"1974","journal-title":"Commun Stat - Theory Methods"},{"key":"10.1016\/j.radonc.2023.109720_b0155","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1002\/onco.13900","article-title":"Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies","volume":"26","author":"Chen","year":"2021","journal-title":"The Oncologist"},{"key":"10.1016\/j.radonc.2023.109720_b0160","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.radonc.2009.01.004","article-title":"Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study","volume":"91","author":"De Ruysscher","year":"2009","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0165","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1007\/s00259-021-05284-5","article-title":"The increasing potential of nuclear medicine imaging for the evaluation and reduction of normal tissue toxicity from radiation treatments","volume":"48","author":"Mohan","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.radonc.2023.109720_b0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1748-717X-9-74","article-title":"Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer","volume":"9","author":"Castillo","year":"2014","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.radonc.2023.109720_b0175","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ijrobp.2010.06.016","article-title":"[18F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients","volume":"81","author":"Petit","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109720_b0180","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.radonc.2016.05.007","article-title":"Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)","volume":"119","author":"Chaudhuri","year":"2016","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0185","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ijrobp.2008.04.002","article-title":"Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response","volume":"71","author":"Hart","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109720_b0190","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3390\/biomedicines9091181","article-title":"Promising biomarkers of radiation-induced lung injury: a review","volume":"9","author":"Liu","year":"2021","journal-title":"Biomedicines"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402300258X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402300258X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:39Z","timestamp":1759123539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402300258X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":38,"alternative-id":["S016781402300258X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109720","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109720"}}